

# The Journal of PHARMACOLOGY

## And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2023

Vol. 387, No. 1

### Contents

#### VIEWPOINT

- Partners in Pain: New Insights into The Role of CGRP Signaling in Cross-Organ Sensitization 1  
*Matthew D. Coates and Margaret A. Vizzard*
- Antinociceptive Effects of an Anti-CGRP Antibody in Rat Models of Colon-Bladder Cross-Organ Sensitization 4  
*Ehsan Noor-Mohammadi, Casey O. Ligon, Kimberly D. Mackenzie, Jennifer Stratton, Sara J. Shnider, and Beverley Greenwood-Van Meerveld*

#### VIEWPOINT

- Fixing a Broken Heart Opens the Door to Developing  $K_{ATP}$  Channel Agonists as Pain Relievers 15  
*Vanessa O. Zambelli and Eric R. Gross*
- $K_{ATP}$  Channel Prodrugs Reduce Inflammatory and Neuropathic Hypersensitivity, Morphine-Induced Hypersensitivity, and Precipitated Withdrawal in Mice 18  
*Alexis Doucette, Kayla Johnson, Shelby Hulke, Sunna Mujteba, Elena Miller, Belle Meyer, Peter I. Dosa, and Amanda H. Klein*

#### SPECIAL SECTION ON QUANTITATIVE SYSTEMS PHARMACOLOGY: A FOUNDATION TO ESTABLISH PRECISION MEDICINE

- Quantitative Systems Pharmacology: A Foundation To Establish Precision Medicine—Editorial 27  
*Annabelle Ballesta and James M. Gallo*
- ☐ Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms 31  
*Gurvan Hermange, Paul-Henry Cournède, and Isabelle Plo*
- ☐ Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation 44  
*David Hodson, Hitesh Mistry, James Yates, Paul Farrington, Anna Staniszewska, Sofia Guzzetti, Michael Davies, Leon Aarons, and Kayode Ogungbenro*
- ☐ A Mathematical Model to Investigate the Effects of Ceralasertib and Olaparib in Targeting the Cellular DNA Damage Response Pathway 55  
*Kira Pugh, Michael Davies, and Gibin Powathil*
- ☐ Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma 66  
*Anudeep Surendran, Adrienne L. Jenner, Elham Karimi, Benoit Fiset, Daniela F. Quail, Logan A. Walsh, and Morgan Craig*
- ☐ Mechanistically Weighted Metric to Predict In Vivo Antibody-Receptor Occupancy: An Analytical Approach 78  
*Eshita Khera, Jaeyeon Kim, Andrew Stein, Matt Ratanapanichkich, and Greg M. Thurber*
- Quantitative Systems Pharmacology and Machine Learning: A Match Made in Heaven or Hell? 92  
*Marcus John Tindall, Lourdes Cucurull-Sanchez, Hitesh Mistry, and James W.T. Yates*

☐ Supplemental material is available at [jpet.aspetjournals.org](http://jpet.aspetjournals.org).

*About the cover:* This represents cancer cells progressing through the cell cycle phases, where they can become damaged, or they can die. See the article by Pugh et al. ([dx.doi.org/10.1124/jpet.122.001558](https://doi.org/10.1124/jpet.122.001558)).

## MINIREVIEW

- Role(s) of G3BPs in Human Pathogenesis 100  
*Chandrani Mukhopadhyay and Pengbo Zhou*

## CELLULAR AND MOLECULAR

- Role of ERK1/2 Signaling in Cinnabarinic Acid-Driven Stanniocalcin 2–Mediated Protection against Alcohol-Induced Apoptosis 111  
*Nikhil Y. Patil, Iulia Rus, and Aditya D. Joshi*

## DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

- ☐ Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COVS.2.S Vaccination in Non-Human Primates 121  
*Anna Dari, Laura Solfrosi, Ramon Roozendaal, Richard M.W. Hoetelmans, Juan-José Pérez-Ruixo, and Muriel Boulton*